---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-029912"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:53:43.532798+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses

## Summary
- Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.
- Part 3A tests one-step titration to 48 mg; Part 3B two-step to 64 mg; primary endpoints safety/tolerability.
- Initial dosing expected April 2026; data readout expected Q4 2026.
- CEO cites prior 48 mg cohort results: ~9% weight loss, improved glycemic control, favorable safety profile.

## SEC filing metadata
- accession: 0001104659-26-029912
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/0001104659-26-029912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/mtva-20260318x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-029912
- JSON: https://secwatch.observer/filing/0001104659-26-029912.json
- Plain text: https://secwatch.observer/filing/0001104659-26-029912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.